AR118729A1 - Inhibidor selectivo de la jak1 quinasa - Google Patents
Inhibidor selectivo de la jak1 quinasaInfo
- Publication number
- AR118729A1 AR118729A1 ARP200101101A ARP200101101A AR118729A1 AR 118729 A1 AR118729 A1 AR 118729A1 AR P200101101 A ARP200101101 A AR P200101101A AR P200101101 A ARP200101101 A AR P200101101A AR 118729 A1 AR118729 A1 AR 118729A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- alkoxy
- nrarb
- hydroxyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de la fórmula (1), y sales farmacéuticamente aceptables de los mismos, que son de utilidad como inhibidores de JAK quinasa. También se divulgan composiciones farmacéuticas que comprenden uno o más compuestos de la fórmula (1), y métodos para utilizar dichos compuestos o composiciones en el tratamiento de condiciones respiratorias (por ejemplo, asma o EPOC). Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1) o una sal farmacéuticamente aceptable del mismo, donde, el anillo A es un heteroarilo monocíclico o anillo bicíclico saturado o insaturado de 8 - 10 miembros que tiene 0 - 5 heteroátomos del anillo seleccionados entre oxígeno, azufre y nitrógeno, donde uno o más grupos -CH₂- que forman parte del heteroarilo, o el anillo bicíclico pueden reemplazarse por un grupo -C(O)-; R¹ es hidrógeno, halógeno, hidroxilo, amino, ciano, o C₁₋₃ alquilo; R² es hidrógeno, C₁₋₁₂ alquilo o C₁₋₁₂ alcoxilo opcionalmente sustituido en forma simple o múltiple con halógeno, hidroxilo, amino, ciano, o C₁₋₁₂ alcoxilo; cada uno de R³ y R⁴ en forma independiente está ausente, o es halógeno, hidroxilo, C₁₋₆ alquilo, carboxilo, C₁₋₆ alcoxilo, C₁₋₆ alcoxicarbonilo, -NRᵃRᵇ, -C(O)NRᵃRᵇ, sulfinilo, C₁₋₆ alquilsulfinilo, sulfonilo, C₁₋₆ alquilsulfonilo, sulfonoxilo, sulfoximinilo, C₁₋₆ alquilsulfoximinilo, sulfonimidoilo, S-(C₁₋₆ alquil)sulfonimidoilo, N-(C₁₋₆ alquil)sulfonimidoilo, N, S-(C₁₋₆ alquil)₂sulfonimidoilo, fosfinoilo, C₁₋₆ alquilfosfinoilo, (C₁₋₆ alquil)₂fosfinoilo, C₁₋₆ alquilfosfonilo, carbociclilo saturado o insaturado de 3 - 10 miembros, heterociclilo saturado o insaturado de 3 - 10 miembros, que puede estar opcionalmente sustituido en forma simple o múltiple en forma independiente con halógeno, hidroxilo, C₁₋₆ alquilo, C₁₋₆ alcoxilo, C₁₋₆ carboxilo, C₁₋₆ alcoxicarbonilo, -NRᵃRᵇ, -C(O)NRᵃRᵇ, sulfonilo, C₁₋₆ alquilsulfonilo, carbamoilo, N-(C₁₋₆ alquil)carbamoilo, o N,N-(C₁₋₆ alquil)₂carbamoilo, fosfinoilo, C₁₋₆ alquilfosfinoilo, (C₁₋₆ alquil)₂fosfinoilo, donde uno o más grupos -CH₂- que forman parte del carbociclilo o heterociclilo pueden reemplazarse por un grupo -C(O)-; donde, cada Rᵃ y Rᵇ se selecciona en forma independiente entre hidrógeno, C₁₋₆ alquilo, C₁₋₆ alquilcarbonilo, que puede estar opcionalmente sustituido en forma simple o múltiple en forma independiente con halógeno, hidroxilo, o C₁₋₆ alcoxi.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019083376 | 2019-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118729A1 true AR118729A1 (es) | 2021-10-27 |
Family
ID=72837031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101101A AR118729A1 (es) | 2019-04-19 | 2020-04-17 | Inhibidor selectivo de la jak1 quinasa |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220220096A1 (es) |
| EP (1) | EP3956322A4 (es) |
| JP (1) | JP2022529061A (es) |
| KR (1) | KR20220003537A (es) |
| CN (1) | CN113710664B (es) |
| AR (1) | AR118729A1 (es) |
| AU (1) | AU2020258619A1 (es) |
| BR (1) | BR112021020964A2 (es) |
| CA (1) | CA3134174A1 (es) |
| MX (1) | MX2021012749A (es) |
| TW (1) | TW202104215A (es) |
| WO (1) | WO2020211839A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023551313A (ja) * | 2020-11-26 | 2023-12-07 | 科輝智薬（深▲セン▼）新薬研究中心有限公司 | アミド化合物、医薬組成物およびその使用 |
| CN114380806B (zh) * | 2022-03-24 | 2022-06-10 | 中国药科大学 | 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用 |
| US20240025884A1 (en) * | 2022-07-05 | 2024-01-25 | Dong-A St Co., Ltd. | Compounds as gcn2 inhibitors, pharmaceutical compositions and uses thereof |
| WO2024013736A1 (en) * | 2022-07-12 | 2024-01-18 | Adama Makhteshim Ltd. | Process for preparing substituted benzamides |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3353168T3 (da) | 2015-09-25 | 2023-10-02 | Dizal Jiangsu Pharmaceutical Co Ltd | Forbindelser og fremgangsmåder til at inhibere jak |
| CR20190332A (es) | 2017-01-17 | 2019-09-13 | Astrazeneca Ab | Inhibidores selectivos de jak1 |
| US20210371415A1 (en) * | 2018-09-21 | 2021-12-02 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | Aromatic heterocyclic compound with kinase inhibitory activity |
-
2020
- 2020-04-17 TW TW109112994A patent/TW202104215A/zh unknown
- 2020-04-17 JP JP2021561927A patent/JP2022529061A/ja active Pending
- 2020-04-17 BR BR112021020964A patent/BR112021020964A2/pt unknown
- 2020-04-17 KR KR1020217036576A patent/KR20220003537A/ko unknown
- 2020-04-17 WO PCT/CN2020/085338 patent/WO2020211839A1/en unknown
- 2020-04-17 CN CN202080029899.3A patent/CN113710664B/zh active Active
- 2020-04-17 US US17/604,442 patent/US20220220096A1/en active Pending
- 2020-04-17 EP EP20790639.7A patent/EP3956322A4/en active Pending
- 2020-04-17 CA CA3134174A patent/CA3134174A1/en active Pending
- 2020-04-17 AU AU2020258619A patent/AU2020258619A1/en active Pending
- 2020-04-17 AR ARP200101101A patent/AR118729A1/es unknown
- 2020-04-17 MX MX2021012749A patent/MX2021012749A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020211839A1 (en) | 2020-10-22 |
| CA3134174A1 (en) | 2020-10-22 |
| US20220220096A1 (en) | 2022-07-14 |
| CN113710664A (zh) | 2021-11-26 |
| AU2020258619A1 (en) | 2021-09-16 |
| EP3956322A1 (en) | 2022-02-23 |
| EP3956322A4 (en) | 2023-05-03 |
| JP2022529061A (ja) | 2022-06-16 |
| MX2021012749A (es) | 2021-11-18 |
| KR20220003537A (ko) | 2022-01-10 |
| BR112021020964A2 (pt) | 2021-12-14 |
| CN113710664B (zh) | 2024-01-26 |
| TW202104215A (zh) | 2021-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR118729A1 (es) | Inhibidor selectivo de la jak1 quinasa | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| SV2016005351A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| PE20180232A1 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue | |
| UY36121A (es) | ?pirazolopiridinas y pirazolopirimidinas?. | |
| PE20160044A1 (es) | Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos | |
| CO7111284A2 (es) | Nucleósidos de espirooxetano de uracilo | |
| CL2020000610A1 (es) | Compuestos de bisamida que activan el sarcómero y sus usos. | |
| AR110088A1 (es) | Inhibidores de magl | |
| AR107927A1 (es) | Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| CO2022008968A2 (es) | Nuevos derivados de metilquinazolinona | |
| AR110753A1 (es) | Inhibidores selectivos de jak1 | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| CU20150084A7 (es) | Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral) | |
| NI202000058A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
| CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| UY37941A (es) | Derivados de bencimidazol y sus usos | |
| PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
| CO2022008719A2 (es) | Compuestos para modular la actividad de fxr y usos de los mismos | |
| ECSP22022958A (es) | Moduladores poliheterociclicos de sting (estimulador de genes de interferón) | |
| CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| PE20212333A1 (es) | Compuestos de acido ascorbico y quinona en combinacion con un agente antiparasitario para el tratamiento de una enfermedad parasitaria |